Affinage

UHMK1

Serine/threonine-protein kinase Kist · UniProt Q8TAS1

Length
419 aa
Mass
46.5 kDa
Annotated
2026-06-10
69 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

UHMK1 (KIS) is a nuclear serine/threonine kinase, distinguished by a C-terminal UHM (U2AF homology motif) domain, that couples cell cycle control to RNA processing (PMID:9287318, PMID:18588901). It preferentially phosphorylates Ser-Pro motifs with a specificity distinct from MAP kinases and CDKs (PMID:10880969). A central function is phosphorylation of the CDK inhibitor p27Kip1 at Ser10, which drives nuclear export of p27 and permits cell cycle progression (PMID:18384876); this activity sits downstream of FoxM1, which transcriptionally induces UHMK1 in a growth-factor-dependent manner, and of PI3K/Rac1 and ERK1/2 signaling (PMID:17984092, PMID:20811053). UHMK1 also phosphorylates stathmin at Ser38 to promote its degradation and limit microtubule-destabilizing activity, a mechanism that restrains vascular smooth muscle cell migration and neointima formation in knockout mice (PMID:19033656). Through its UHM domain UHMK1 binds the splicing factors SF1 and SF3b155 with U2AF65-like efficiency (PMID:18588901), and phosphoproteomic and RNA-seq analyses establish it as a splicing-regulatory kinase that targets spliceosome components and controls hundreds of alternative splicing events, including EMT-related exons (PMID:36803961); in neurons it phosphorylates PTBP2, disrupting its complex with Matrin3 and hnRNPM and counteracting PTBP2-mediated exon exclusion during differentiation (PMID:38597390). UHMK1 additionally localizes to neuronal RNA granules with KIF3A, NonO and eEF1A to stimulate local translation and support neurite outgrowth and spine development, in part by antagonizing the translational repressor CPEB3 (PMID:19015237, PMID:25319695). In cancer, UHMK1 is induced by YAP/FOXM1 and SOX4 and acts through multiple effectors—enriching MYBL2 in the nucleus to drive cell cycle gene expression (PMID:30936457), phosphorylating NCOA3 to activate ATF4-dependent purine and one-carbon metabolism (PMID:31975428, PMID:40918462), and engaging STAT3 and stathmin-dependent signaling (PMID:35501324, PMID:41966283). Additional substrates including CATS/FAM64A and the Cajal body protein coilin extend its reach to transcriptional repression and Cajal body dynamics (PMID:23419774, PMID:35151311).

Mechanistic history

Synthesis pass · year-by-year structured walk · 21 steps
  1. 1997 High

    Establishing UHMK1 as a kinase with an RNA-recognition motif first defined the protein's dual identity, linking a stathmin-binding activity to a potential RNA-processing function.

    Evidence Two-hybrid identification of the stathmin interaction, in vitro kinase assays on stathmin/MBP/synapsin, and fractionation showing nuclear targeting

    PMID:9287318

    Open questions at the time
    • In vitro substrates not yet validated as physiological
    • Functional role of the UHM/RRM domain undefined
  2. 2000 High

    Defining UHMK1's preference for Ser-Pro motifs, distinct from MAP kinases and CDKs, gave it a substrate-recognition logic and a mapped phosphosite on MBP.

    Evidence In vitro kinase assay with mass spectrometry and phosphopeptide mapping

    PMID:10880969

    Open questions at the time
    • Consensus determined on model substrates, not endogenous targets
    • Regulation of autophosphorylation by histones not mechanistically explained
  3. 2007 High

    Identifying UHMK1 as a direct FoxM1 transcriptional target placed it within a growth-factor-driven program controlling p27Kip1 localization and cell cycle entry.

    Evidence FoxM1 deletion/siRNA, immunoblotting and promoter/reporter analysis in cells

    PMID:17984092

    Open questions at the time
    • Direct kinase action on p27 not addressed in this study
    • Other upstream transcriptional inputs unexplored
  4. 2008 High

    Domain mapping showed the kinase domain drives nuclear localization while the UHM domain mediates SF1/SF3b155 binding, mechanistically tying UHMK1 to the spliceosome.

    Evidence Deletion/mutation localization constructs, GST pull-down and co-IP with splicing factors

    PMID:18588901

    Open questions at the time
    • Whether SF1/SF3b155 are phosphorylation substrates not established here
    • Functional consequence for splicing not measured
  5. 2008 High

    The KIS knockout mouse established a physiological in vivo function: phosphorylation of stathmin Ser38 to limit VSMC migration and p27-dependent proliferation in vascular injury.

    Evidence KIS-/- mice in a vascular injury model with stathmin knockdown rescue (epistasis)

    PMID:19033656

    Open questions at the time
    • Tissue-specific roles beyond vasculature not addressed
    • Balance between stathmin and p27 arms not quantified
  6. 2008 High

    Direct phosphorylation of p27Kip1 at Ser10 by UHMK1 connected its kinase activity to suppression of the G0/G1 arrest, demonstrated in leukemia cells.

    Evidence Co-IP, kinase assay, siRNA knockdown with cell cycle analysis

    PMID:18384876

    Open questions at the time
    • Nuclear export step downstream of S10 not directly shown in this system
  7. 2008 High

    Localization to neuronal RNA granules with KIF3A, NonO and eEF1A revealed a cytoplasmic role in mRNA transport and local translation supporting neurite outgrowth.

    Evidence Co-IP from brain extracts, colocalization imaging, knockdown and local translation reporters

    PMID:19015237

    Open questions at the time
    • Granule substrate(s) phosphorylated by KIS not identified
    • Mechanism coupling kinase activity to translation unclear
  8. 2010 Medium

    FRAP and substrate studies showed UHMK1 cycles rapidly between nucleus and cytosol, and cytosolic UHMK1 phosphorylates the PAM cytosolic domain to control its nuclear access and POMC processing.

    Evidence FRAP, phosphomimetic mutations, overexpression and microarray in endocrine cells

    PMID:20573687

    Open questions at the time
    • PAM phosphorylation site not mapped by mass spectrometry
    • Direct kinase-substrate relationship inferred, not reconstituted
  9. 2011 Medium

    Placing UHMK1-driven p27 Ser10 phosphorylation downstream of PI3K/Rac1 and ERK1/2 integrated it into FGF-2-stimulated proliferative signaling.

    Evidence siRNA, Rac1-GTP pull-down, phospho-p27 immunoblot and proliferation assays with pathway inhibitors

    PMID:20811053

    Open questions at the time
    • Direct linkage between the kinases and UHMK1 activation not biochemically defined
    • Single cell type
  10. 2013 High

    Identifying CATS/FAM64A as a Ser131 substrate and transcriptional partner extended UHMK1's influence to transcriptional repression and CALM/AF10 antagonism.

    Evidence Two-hybrid, pull-down, co-IP, in vitro kinase assay with site mapping and reporter assays

    PMID:23419774

    Open questions at the time
    • Functional role of S131 phosphorylation unresolved (transcriptional effect was phosphorylation-independent)
  11. 2014 High

    In hippocampal neurons UHMK1 was shown to counteract CPEB3 repression of GluR2 translation, linking its kinase activity to spine development and synaptic strength.

    Evidence KIS knockdown, spine morphology, fractionation and CPEB3 epistasis/translation reporters

    PMID:25319695

    Open questions at the time
    • Whether CPEB3 is a direct UHMK1 substrate not established
    • Molecular step relieving CPEB3 repression undefined
  12. 2015 Medium

    A MARCKS-UHMK1 axis was placed upstream of p27 control, with kinase-dead rescue confirming UHMK1 catalytic activity as the essential effector of VSMC proliferation.

    Evidence siRNA, kinase-dead rescue, nuclear fractionation, BrdU and vascular injury model

    PMID:26528715

    Open questions at the time
    • Mechanism by which MARCKS controls UHMK1 levels not defined
    • Direct vs indirect MARCKS-UHMK1 link unclear
  13. 2019 High

    The YAP/FOXM1-UHMK1-MYBL2 axis defined an oncogenic role in hepatocellular carcinoma, with UHMK1 enriching MYBL2 in the nucleus to drive cell cycle genes.

    Evidence BioID/MS, co-IP, reporter assays, nuclear fractionation and YAP-transgenic mice with HCC tissue

    PMID:30936457

    Open questions at the time
    • Whether MYBL2 is a phosphorylation substrate not shown
    • Mechanism of MYBL2 nuclear enrichment not defined
  14. 2020 High

    Mapping NCOA3 Ser1062/Thr1067 phosphorylation linked UHMK1 to ATF4-driven de novo purine synthesis and gastric cancer progression.

    Evidence Site mutagenesis, co-IP, in vitro kinase assay, pathway-inhibitor rescue, xenografts and human tissue

    PMID:31975428

    Open questions at the time
    • Upstream signals activating this axis in tumors not defined
  15. 2022 Medium

    A UHMK1-STAT3 positive feedback loop was shown to support colorectal cancer proliferation and oxaliplatin resistance.

    Evidence Co-IP, knockdown/overexpression, reporter and drug-sensitivity assays

    PMID:35501324

    Open questions at the time
    • Mechanism of STAT3 activation not biochemically defined
    • Whether STAT3 is a substrate unknown
  16. 2022 Medium

    Phosphorylation of coilin connected UHMK1 to Cajal body dynamics and 5-FU-responsive alternative splicing in colon cancer.

    Evidence Phosphorylation assay, immunofluorescence of Cajal bodies, splicing and viability assays

    PMID:35151311

    Open questions at the time
    • Coilin phosphosite not mapped by mutagenesis
    • Single study, single lab
  17. 2023 High

    Global phosphoproteomics and RNA-seq established UHMK1 as a bona fide splicing-regulatory kinase targeting spliceosome components and controlling hundreds of alternative splicing events.

    Evidence Phosphoproteomics, RNA-seq, splicing reporter and siRNA in cells

    PMID:36803961

    Open questions at the time
    • Direct vs indirect status of many putative substrates unverified
    • Functional consequences of individual splicing changes not dissected
  18. 2024 High

    Phosphorylation of PTBP2 provided a mechanistic basis for UHMK1's splicing control in neurons by dissociating PTBP2 from Matrin3/hnRNPM and reducing RNA binding during differentiation.

    Evidence In vitro kinase assay, RNA-seq, co-IP, RNA-binding assay and KIS/PTBP2 epistasis on spine maturation

    PMID:38597390

    Open questions at the time
    • Specific phosphosites on PTBP2 not enumerated here
    • Generality to non-neuronal PTB proteins untested
  19. 2024 Low

    SOX4 was identified as an additional transcriptional activator of UHMK1, with UHMK1 promoting lung adenocarcinoma growth via ID1/β-catenin signaling.

    Evidence Dual luciferase, RT-qPCR, western blot, knockdown/overexpression and xenografts

    PMID:39052126

    Open questions at the time
    • ID1/β-catenin connection not mechanistically dissected; single lab, single study
    • Direct UHMK1 substrate in this pathway unidentified
  20. 2025 Medium

    A UHMK1-NCOA3-ATF4-MTHFD2 axis with positive feedback extended the metabolic-coactivator mechanism to one-carbon metabolism in prostate cancer.

    Evidence Co-IP, in vitro kinase assay, knockdown/overexpression and xenografts

    PMID:40918462

    Open questions at the time
    • NCOA3 phosphosite not mapped by mutagenesis in this study
    • Single lab, single study
  21. 2026 Medium

    UHMK1 was shown to stabilize STMN1 against proteasomal degradation and to co-activate PI3K/AKT/mTOR signaling driving vasculogenic mimicry in oral squamous cell carcinoma.

    Evidence Co-IP, ubiquitination/proteasome-inhibitor assay, knockdown, VM assay and IHC

    PMID:41966283

    Open questions at the time
    • Ubiquitination sites and whether stabilization requires kinase activity not established
    • Reconciliation with prior stathmin-degradation role unaddressed

Open questions

Synthesis pass · forward-looking unresolved questions
  • How UHMK1 dynamically partitions between its nuclear cell-cycle/splicing functions and cytoplasmic RNA-granule/translation functions, and what governs substrate selection across these compartments, remains unresolved.
  • No structural model linking UHM-domain docking to substrate phosphorylation
  • Signals controlling nucleocytoplasmic cycling not defined
  • Direct vs indirect status of many proposed substrates unverified

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 7 GO:0016740 transferase activity 5 GO:0003723 RNA binding 3 GO:0008092 cytoskeletal protein binding 3 GO:0140657 ATP-dependent activity 1
Localization
GO:0005634 nucleus 3 GO:0005730 nucleolus 1 GO:0005829 cytosol 1 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1640170 Cell Cycle 4 R-HSA-1643685 Disease 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-8953854 Metabolism of RNA 3
Partners
CDKN1BFAM64AMYBL2NCOA3PTBP2SF1SF3B1STMN1

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 KIS (UHMK1) was identified as a serine/threonine kinase possessing an RNP-type RNA recognition motif (UHM domain). KIS was originally isolated through its interaction with stathmin in a two-hybrid screen. Bacterially produced KIS has autophosphorylating activity and phosphorylates stathmin on serine residues, as well as myelin basic protein and synapsin in vitro. Immunofluorescence and biochemical fractionation showed KIS is partly targeted to the nucleus when overexpressed in HEK293 cells. Two-hybrid screen, in vitro kinase assay, immunofluorescence, biochemical fractionation The Journal of biological chemistry High 9287318
2000 KIS preferentially phosphorylates Ser-Pro motifs but has a specificity distinct from MAP kinases and CDKs. Mass spectrometry identified serine 164 of MBP as the unique site phosphorylated by KIS. A Ser-Pro motif in synapsin I was also phosphorylated. Histones inhibit KIS autophosphorylation. In vitro kinase assay, mass spectrometry, peptide sequencing, phosphopeptide mapping European journal of biochemistry High 10880969
2007 FoxM1 transcription factor directly regulates KIS expression in a growth factor-dependent manner. Loss of FoxM1 (deletion or siRNA) impairs KIS expression and leads to nuclear accumulation of p27(Kip1). KIS is a direct transcriptional target of FoxM1, providing a mechanism by which FoxM1 promotes cell cycle progression through p27 regulation. siRNA knockdown, FoxM1 deletion cells, immunoblotting, transcriptional reporter assay, promoter analysis The Journal of biological chemistry High 17984092
2008 The kinase domain of KIS is necessary for its nuclear localization, while the C-terminal UHM domain is required for binding to splicing factors SF1 and SF3b155. KIS binds SF1 and SF3b155 with efficiency similar to U2AF65 in pull-down assays. KIS shows different specificity for UHM docking sites in SF3b155 compared to other UHM-containing proteins. Subcellular localization of KIS deletion/mutation constructs, GST pull-down assays, co-immunoprecipitation Journal of molecular biology High 18588901
2008 KIS protects against vascular neointima formation by phosphorylating stathmin at serine 38, which promotes stathmin protein degradation and reduces cytoplasmic tubulin-destabilizing activity. KIS-/- mice show accelerated neointima formation after vascular injury, increased VSMC migration, increased stathmin levels, and abolished VSMC proliferation due to delayed nuclear export and degradation of p27Kip1. Downregulation of stathmin in KIS-/- VSMCs fully restored the normal phenotype. KIS knockout mice, vascular injury model, siRNA knockdown of stathmin, VSMC migration assay, immunoblotting, phosphorylation site identification The Journal of clinical investigation High 19033656
2008 KIS localizes to RNA granules in cortical neurons and colocalizes with the KIF3A kinesin and beta-actin mRNA. KIS interacts with KIF3A, NonO, and eEF1A (components of RNA granules) by co-immunoprecipitation from brain extracts. KIS knockdown impairs neurite outgrowth, and KIS kinase activity stimulates 3'UTR-dependent local translation in neuritic projections. Co-immunoprecipitation, live imaging/colocalization, siRNA knockdown, neurite outgrowth assay, local translation reporter assay Molecular and cellular biology High 19015237
2008 KIS directly interacts with p27Kip1 protein and phosphorylates p27 at serine 10 (S10). Reduction of KIS by siRNA inhibits S10 phosphorylation, strongly suppresses cell proliferation, and increases the G0/G1 fraction in leukemia cells. Co-immunoprecipitation, siRNA knockdown, kinase assay, cell cycle analysis (flow cytometry), proliferation assay Leukemia research High 18384876
2010 Uhmk1 basally phosphorylates the cytosolic domain (CD) of PAM (peptidylglycine alpha-amidating monooxygenase), a secretory granule membrane enzyme. Uhmk1 is concentrated in the nucleus but cycles rapidly between nucleus and cytosol (FRAP). Phosphomimetic mutations in PAM-CD or simultaneous overexpression of active Uhmk1 reduces nuclear localization of soluble PAM-CD. Membrane-tethered Uhmk1 retains the ability to exclude PAM-CD from the nucleus, suggesting cytosolic Uhmk1 mediates this response. Uhmk1 knockdown increases POMC processing and reduces Aqp1 expression. FRAP (live imaging), phosphomimetic mutations, co-expression/overexpression, microarray analysis, immunofluorescence Molecular endocrinology Medium 20573687
2011 KIS phosphorylates p27 at Ser10 downstream of both the PI3K/Rac1 and ERK1/2 pathways in FGF-2-stimulated corneal endothelial cells. siRNA knockdown of KIS specifically inhibited Ser10 phosphorylation and FGF-2-stimulated cell proliferation. KIS expression was induced during early G1 by both pathways. siRNA knockdown of KIS, GTP pull-down (Rac1-GTP), immunoblotting for phospho-p27, MTT proliferation assay, Cdc25A and kinase inhibitors Investigative ophthalmology & visual science Medium 20811053
2013 CATS (FAM64A) protein was identified as a substrate of KIS/UHMK1. The interaction between CATS and KIS was confirmed by GST pull-down, co-immunoprecipitation, and colocalization. In vitro kinase assay mapped the KIS phosphorylation site to CATS serine 131 (S131). KIS and CATS expression change in opposite directions during the cell cycle. In a reporter assay, KIS enhanced the transcriptional repressor activity of CATS independently of S131 phosphorylation, and both CATS and KIS antagonize the transactivation capacity of CALM/AF10. Yeast two-hybrid screen, GST pull-down, co-immunoprecipitation, colocalization, in vitro kinase assay, phosphorylation site mapping, reporter gene assay Biochimica et biophysica acta High 23419774
2014 KIS downregulation in hippocampal neurons compromises spine development, alters actin dynamics, and reduces postsynaptic responsiveness. KIS absence decreases protein levels of PSD-95, GluR1, and GluR2 in a CPEB3-dependent manner. KIS counteracts the inhibitory activity of CPEB3 on GluR2 3'UTR translation and polyadenylation. KIS suppresses spine developmental defects caused by CPEB3 overexpression (genetic epistasis). KIS knockdown in mice, spine morphology analysis, biochemical fractionation, CPEB3 overexpression/rescue experiments, translation reporter assay The Journal of neuroscience High 25319695
2015 MARCKS knockdown decreases KIS expression in VSMCs, leading to reduced phosphorylation of p27Kip1 at Ser10, nuclear trapping of p27Kip1, and cell cycle arrest. Overexpression of KIS (but not catalytically inactive KIS) rescues the p27Kip1 nuclear trapping and cell cycle arrest caused by MARCKS knockdown, establishing KIS kinase activity as the essential downstream effector of MARCKS in VSMC proliferation. siRNA knockdown, KIS overexpression with kinase-dead mutant, nuclear fractionation, BrdU incorporation, vascular injury model PloS one Medium 26528715
2019 UHMK1 is a direct transcriptional target of YAP and FOXM1 in hepatocellular carcinoma cells. Using BioID labeling and mass spectrometry, MYBL2 (B-MYB) was identified as a direct UHMK1 interaction partner. UHMK1 stimulates nuclear enrichment of MYBL2, which promotes expression of cell cycle regulators CCNB1, CCNB2, KIF20A, and MAD2L1. This YAP-UHMK1-MYBL2 pathway was confirmed in YAPS127A-transgenic mice and human HCC tissues. BioID proximity labeling, mass spectrometry, co-immunoprecipitation, transcriptional reporter assay, nuclear fractionation, transgenic mouse model Oncogene High 30936457
2020 UHMK1 promotes gastric cancer progression by activating de novo purine synthesis. Mechanistically, UHMK1 phosphorylates NCOA3 at Ser1062 and Thr1067, which enhances NCOA3 binding to the transcription factor ATF4 and increases expression of purine metabolism genes. Phosphorylation-deficient NCOA3 (S1062A/T1067A) abrogates UHMK1-driven gastric cancer progression. Phospho-NCOA3 levels correlate with UHMK1 levels in human GC specimens. siRNA knockdown, phosphorylation site mutagenesis, co-immunoprecipitation, in vitro kinase assay, purine synthesis inhibitor rescue, xenograft models, human tissue analysis The EMBO journal High 31975428
2022 UHMK1 interacts with STAT3 and enhances STAT3 transcriptional activity in colorectal cancer cells. STAT3 in turn transcriptionally activates UHMK1 expression, establishing a positive feedback regulatory loop. UHMK1 knockdown restrained CRC cell proliferation and increased oxaliplatin sensitivity, while overexpression had the opposite effects. Co-immunoprecipitation, siRNA knockdown, overexpression, transcriptional reporter assay, proliferation assay, drug sensitivity assay Cell death & disease Medium 35501324
2022 UHMK1 phosphorylates coilin (a major Cajal body component), alters Cajal body assembly and disassembly, and regulates alternative RNA splicing events that affect cell survival following 5-FU treatment in colon cancer cells. Phosphorylation assay, immunofluorescence (Cajal body morphology), alternative splicing analysis, cell viability assay Cell communication and signaling Medium 35151311
2023 UHMK1 is a splicing regulatory kinase. Global phosphoproteomic analysis upon UHMK1 modulation identified 163 differentially phosphorylated sites in 117 proteins, including 106 novel putative substrates enriched for spliceosome components. RNA-seq showed UHMK1 affects over 270 alternative splicing events. Splicing reporter assay confirmed UHMK1 function in splicing. UHMK1 knockdown had minor effects on transcript abundance but impacted epithelial-mesenchymal transition-related splicing. Global phosphoproteomics (MS), RNA-seq, splicing reporter assay, siRNA knockdown, bioinformatics The Journal of biological chemistry High 36803961
2024 KIS phosphorylates PTBP2 in neurons, counteracting PTBP2-mediated exon exclusion genome-wide during neuronal differentiation. Phosphorylation of unstructured domains within PTBP2 causes its dissociation from co-regulators Matrin3 and hnRNPM and reduces the RNA-binding capability of the complex. KIS and PTBP2 display strong opposing functional interactions in synaptic spine emergence and maturation (epistasis). In vitro kinase assay, RNA-seq, co-immunoprecipitation, RNA-binding assay, spine morphology analysis, genetic epistasis (double manipulation of KIS and PTBP2) eLife High 38597390
2024 KIS (UHMK1) is transcriptionally activated by SOX4 in lung adenocarcinoma cells. KIS activates the β-catenin signaling pathway by modulating ID1. KIS overexpression promotes LUAD cell proliferation, migration, and invasion, while knockdown suppresses these phenotypes. Dual-luciferase assay confirmed transcriptional regulation of KIS by SOX4. Dual luciferase assay, RT-qPCR, western blot, siRNA knockdown, overexpression, xenograft model Journal of cancer research and clinical oncology Low 39052126
2025 UHMK1 phosphorylates NCOA3 (nuclear receptor coactivator 3), which activates ATF4 to upregulate MTHFD2 transcription in prostate cancer cells. MTHFD2 reciprocally enhances UHMK1 expression, forming a positive feedback loop. This was established by kinase assay, co-immunoprecipitation, and rescue experiments. Co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, overexpression, xenograft model Oncology research Medium 40918462
2026 UHMK1 interacts with stathmin 1 (STMN1) in OSCC cells, confirmed by co-immunoprecipitation. UHMK1 stabilizes STMN1 protein expression by inhibiting its ubiquitin-proteasome degradation. UHMK1 and STMN1 together activate the PI3K/AKT/mTOR signaling pathway to regulate vasculogenic mimicry (VM) formation. Co-immunoprecipitation, ubiquitination assay (proteasome inhibitor), siRNA knockdown, VM formation assay, immunohistochemistry Biochimica et biophysica acta. Molecular basis of disease Medium 41966283

Source papers

Stage 0 corpus · 69 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1983 Frequent activation of c-kis as a transforming gene in fibrosarcomas induced by methylcholanthrene. Science (New York, N.Y.) 102 6302839
1991 The kis and kid genes of the parD maintenance system of plasmid R1 form an operon that is autoregulated at the level of transcription by the co-ordinated action of the Kis and Kid proteins. Molecular microbiology 63 1779758
2002 A novel higher plant protein tyrosine phosphatase interacts with SNF1-related protein kinases via a KIS (kinase interaction sequence) domain. The Plant journal : for cell and molecular biology 60 12148529
2003 Regulatable killing of eukaryotic cells by the prokaryotic proteins Kid and Kis. The EMBO journal 58 12514130
2019 YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. Oncogene 57 30936457
2006 AKINbetagamma contributes to SnRK1 heterotrimeric complexes and interacts with two proteins implicated in plant pathogen resistance through its KIS/GBD sequence. Plant physiology 57 17028154
2006 The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Molecular pharmacology 56 16551782
2007 Interactions of Kid-Kis toxin-antitoxin complexes with the parD operator-promoter region of plasmid R1 are piloted by the Kis antitoxin and tuned by the stoichiometry of Kid-Kis oligomers. Nucleic acids research 55 17317682
2007 FoxM1 regulates growth factor-induced expression of kinase-interacting stathmin (KIS) to promote cell cycle progression. The Journal of biological chemistry 51 17984092
1997 KIS is a protein kinase with an RNA recognition motif. The Journal of biological chemistry 46 9287318
2020 UHMK1 promotes gastric cancer progression through reprogramming nucleotide metabolism. The EMBO journal 41 31975428
2011 PI 3-kinase/Rac1 and ERK1/2 regulate FGF-2-mediated cell proliferation through phosphorylation of p27 at Ser10 by KIS and at Thr187 by Cdc25A/Cdk2. Investigative ophthalmology & visual science 38 20811053
2010 Signaling from the secretory granule to the nucleus: Uhmk1 and PAM. Molecular endocrinology (Baltimore, Md.) 38 20573687
2017 Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. European journal of medicinal chemistry 36 29202407
2008 KIS protects against adverse vascular remodeling by opposing stathmin-mediated VSMC migration in mice. The Journal of clinical investigation 35 19033656
2008 Different requirements of the kinase and UHM domains of KIS for its nuclear localization and binding to splicing factors. Journal of molecular biology 34 18588901
2021 Long Non-coding RNA EBLN3P Regulates UHMK1 Expression by Sponging miR-323a-3p and Promotes Colorectal Cancer Progression. Frontiers in medicine 33 34109193
2006 Fine mapping by genetic association implicates the chromosome 1q23.3 gene UHMK1, encoding a serine/threonine protein kinase, as a novel schizophrenia susceptibility gene. Biological psychiatry 33 16978587
2007 Structure and function of bacterial kid-kis and related toxin-antitoxin systems. Protein and peptide letters 30 17305597
2007 Interactions between the toxin Kid of the bacterial parD system and the antitoxins Kis and MazE. Proteins 26 17206710
2021 Correction: Kis, Z. et al. Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. Vaccines 2021, 9, 3. Vaccines 25 33804590
2020 COX5B-Mediated Bioenergetic Alteration Regulates Tumor Growth and Migration by Modulating AMPK-UHMK1-ERK Cascade in Hepatoma. Cancers 24 32580279
2013 The CATS (FAM64A) protein is a substrate of the Kinase Interacting Stathmin (KIS). Biochimica et biophysica acta 24 23419774
2008 Protein kinase KIS localizes to RNA granules and enhances local translation. Molecular and cellular biology 24 19015237
2003 Quantitative RT-PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and human. Brain research. Molecular brain research 24 12782393
2022 UHMK1 aids colorectal cancer cell proliferation and chemoresistance through augmenting IL-6/STAT3 signaling. Cell death & disease 23 35501324
2014 KIS, a kinase associated with microtubule regulators, enhances translation of AMPA receptors and stimulates dendritic spine remodeling. The Journal of neuroscience : the official journal of the Society for Neuroscience 23 25319695
2000 Specific Ser-Pro phosphorylation by the RNA-recognition motif containing kinase KIS. European journal of biochemistry 21 10880969
2008 KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells. Leukemia research 18 18384876
2015 MARCKS Signaling Differentially Regulates Vascular Smooth Muscle and Endothelial Cell Proliferation through a KIS-, p27kip1- Dependent Mechanism. PloS one 17 26528715
2009 Maize AKINbetagamma dimerizes through the KIS/CBM domain and assembles into SnRK1 complexes. FEBS letters 17 19450586
2008 Confirmation of the genetic association between the U2AF homology motif (UHM) kinase 1 (UHMK1) gene and schizophrenia on chromosome 1q23.3. European journal of human genetics : EJHG 16 18414510
2016 Genome-wide association study in East Asians suggests UHMK1 as a novel bone mineral density susceptibility gene. Bone 14 27424934
2018 The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation. Biochimica et biophysica acta. Molecular basis of disease 10 29307747
2023 UHMK1 is a novel splicing regulatory kinase. The Journal of biological chemistry 9 36803961
2022 UHMK1-dependent phosphorylation of Cajal body protein coilin alters 5-FU sensitivity in colon cancer cells. Cell communication and signaling : CCS 9 35151311
2021 Colonization and Authentication of the Pyrethroid-Resistant Anopheles gambiae s.s. Muleba-Kis Strain; an Important Test System for Laboratory Screening of New Insecticides. Insects 9 34442276
2015 Coupling between the basic replicon and the Kis-Kid maintenance system of plasmid R1: modulation by Kis antitoxin levels and involvement in control of plasmid replication. Toxins 9 25664511
2012 Kis antitoxin couples plasmid R1 replication and parD (kis,kid) maintenance modules. Plasmid 9 22244926
2009 Expression of kinase interacting with stathmin (KIS, UHMK1) in human brain and lymphoblasts: Effects of schizophrenia and genotype. Brain research 8 19747464
2023 UHMK1 promotes lung adenocarcinoma oncogenesis by regulating the PI3K/AKT/mTOR signaling pathway. Thoracic cancer 7 36919755
2011 Genetic and molecular exploration of UHMK1 in schizophrenic patients. Psychiatric genetics 7 21399567
2000 New positive selection system based on the parD (kis/kid) system of the R1 plasmid. BioTechniques 7 10769758
2023 Synthesis, crystal structure and thermal behavior of tetra-kis-(3-cyano-pyridine N-oxide-κO)bis-(thio-cyanato-κN)cobalt(II), which shows strong pseudo-symmetry. Acta crystallographica. Section E, Crystallographic communications 5 37817952
2021 Functional characterization of Kid-Kis and MazF-MazE in Sf9 cells and Mythimna separata embryos. Pesticide biochemistry and physiology 3 33838714
1996 A monoclonal antibody KIS-1 recognizing a new membrane antigen on human squamous-cell carcinoma. International journal of cancer 3 8647619
2025 UHMK1 Promotes Prostate Cancer Progression through a Positive Feedback Loop with MTHFD2. Oncology research 2 40918462
2024 KIS counteracts PTBP2 and regulates alternative exon usage in neurons. eLife 2 38597390
2022 Crystal structure and void analysis of tris-(2-amino-1-methyl-benzimidazolium) hexa-kis-(nitrato-κ2 O,O')lanthanate(III). Acta crystallographica. Section E, Crystallographic communications 2 36072139
2021 A new tetra-kis-substituted pyrazine carb-oxy-lic acid, 3,3',3'',3'''-{[pyrazine-2,3,5,6-tetra-yltetra-kis(methyl-ene)]tetra-kis-(sulfanedi-yl)}tetra-propionic acid: crystal structures of two triclinic polymorphs and of two potassium-organic frameworks. Acta crystallographica. Section E, Crystallographic communications 2 34026250
2024 KIS, a target of SOX4, regulates the ID1-mediated enhancement of β-catenin to facilitate lung adenocarcinoma cell proliferation and metastasis. Journal of cancer research and clinical oncology 1 39052126
2016 Crystal structure of bis-[tetra-kis-(tri-phenyl-phosphane-κP)silver(I)] (nitrilo-tri-acetato-κ(4) N,O,O',O'')(tri-phenyl-phosphane-κP)argentate(I) with an unknown amount of methanol as solvate. Acta crystallographica. Section E, Crystallographic communications 1 27006796
2015 Lack of KIs virus DNA in plasma and cerebrospinal fluid in Italy. The new microbiologica 1 26485020
2014 Crystal structure of tetra-kis-(μ-n-butyrato-κ(2) O:O')bis-[chlorido-rhenium(III)](Re-Re). Acta crystallographica. Section E, Structure reports online 1 25484675
2012 5,10,15,20-Tetra-kis(4-acetyl-oxyphen-yl)porphyrin including an unknown solvate. Acta crystallographica. Section E, Structure reports online 1 23476273
2026 EIF4A3-induced circEIF2S2 facilitates colorectal cancer growth, metastasis, and immune suppression via the miR-646/UHMK1 Axis. International journal of biological macromolecules 0 41544785
2026 Cancer continues to be a major global health challenge, driving the need for innovative and precise therapeutic approaches. Protein kinases, which orchestrate vital cellular functions including cell division, survival, and metastasis, are frequently altered in malignancies, positioning them as highly promising targets for cancer treatment. Kinase inhibitors (KIs) have emerged as a powerful class of targeted therapies, demonstrating enhanced effectiveness and reduced systemic toxicity compar. Medicinal chemistry (Shariqah (United Arab Emirates)) 0 41863490
2026 UHMK1 regulates VM formation in OSCC by interacting with STMN1. Biochimica et biophysica acta. Molecular basis of disease 0 41966283
2024 Crystal structure of tetra-phenyl phosphate tetra-kis-[dimethyl (2,2,2-tri-chloro-acet-yl)phos-pho-ramidato]lutetium(III), PPh4[LuL4]. Acta crystallographica. Section E, Crystallographic communications 0 38584743
2024 trans-Di-bromido-tetra-kis-(5-methyl-1H-pyrazole-κN2)manganese(II). IUCrData 0 38586519
2024 Tetra-kis(2,4,6-tri-methyl-anilido)tin(IV). IUCrData 0 38846557
2023 Synthesis, crystal structure and thermal decomposition pathway of bis-(iso-seleno-cyanato-κN)tetra-kis-(pyridine-κN)manganese(II). Acta crystallographica. Section E, Crystallographic communications 0 37151823
2021 Crystal structures of 9-[bis-(benzyl-sulfan-yl)meth-yl]anthracene and of cyclo-dodeca-kis-(μ2-phenyl-methane-thiol-ato-κ2 S:S)hexa-palladium(6 Pd-Pd)-anthracene-9,10-dione (1/1). Acta crystallographica. Section E, Crystallographic communications 0 34513018
2021 Di-μ-benzoato-di-μ-ethano-lato-tetra-kis-[μ3-5-(hy-droxy-meth-yl)-2-methyl-4-(oxidometh-yl)pyridin-1-ium-3-olato]tetra-kis-[μ3-5-(hy-droxy-meth-yl)-2-methyl-4-(oxidometh-yl)pyridin-3-olato]di-μ3-oxido-hepta-manganese(II,III) ethanol octa-solvate. IUCrData 0 36340470
2018 Crystal structure and Hirshfeld surface analysis of 2,4,6,11-tetra-kis-(4-fluoro-phen-yl)-9-oxa-1,5-di-aza-tri-cyclo-[5.3.1.03.8]undeca-ne. Acta crystallographica. Section E, Crystallographic communications 0 30574390
2014 Tetra-μ3-iodido-tetra-kis-[(tri-n-butyl-phosphane-κP)copper(I)]. Acta crystallographica. Section E, Structure reports online 0 24826086
2014 3,10,14,21-Tetra-kis(4-meth-oxy-phen-yl)penta-cyclo-[11.8.0.0(2,11).0(4,9).0(15,20)]henicosa-1(21),2,4(9),5,7,10,13,15(20),16,18-decaen-12-one chloro-form monosolvate. Acta crystallographica. Section E, Structure reports online 0 25249919
2012 Decacarbon-yl[μ(4)-(ethane-1,2-diyl-dinitrilo)-tetra-kis-(methane-thiol-ato)]bis(triphenyl-phosphane)tetra-iron(2 Fe-Fe). Acta crystallographica. Section E, Structure reports online 0 22346806
2012 Tetra-kis[μ(3)-4-nitro-N-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamidato]tetra-kis-[methano-lsodium(I)]. Acta crystallographica. Section E, Structure reports online 0 22590086

Missed literature

Know a paper Affinage missed for UHMK1? Flag it for the maintainers and the community.

No submissions yet.